Filing Flows › Alnylam Pharmaceuticals (ALNY) › Operating margin
Alnylam Pharmaceuticals (ALNY) operating margin by quarter
Alnylam Pharmaceuticals' operating margin was 23.7% in Q3 2026 (third quarter 2026), +5.8 pts from Q2 2026. Over the last 4 quarters it ranged from 12.0% (Q4 2025) to 29.5% (Q3 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 23.7% | +5.8 pts | -5.7 pts |
| Q2 2026 | 17.9% | +5.9 pts | — |
| Q4 2025 | 12.0% | -17.5 pts | — |
| Q3 2025 | 29.5% | — | — |
Q3 2026 at a glance
Alnylam Pharmaceuticals, Q3 2026: revenue $1.5B (+17% year over year), operating margin 23.7%, net earnings $2.2B, operating cash flow $341M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alnylam Pharmaceuticals' operating margin?
Alnylam Pharmaceuticals' operating margin was 23.7% in Q3 2026 (third quarter 2026), +5.8 pts from Q2 2026.
How has Alnylam Pharmaceuticals' operating margin changed?
Over the last 4 quarters it ranged from 12.0% (Q4 2025) to 29.5% (Q3 2025).
Q3 2026 results → · How Alnylam Pharmaceuticals makes money →